10.24.24 -- If The CDMO Shoe Fits, Wear It Now

While the trend toward CB1 inhibition for obesity took a small hit with the release of Novo Nordisk's small molecule oral cannabinoid receptor (CB1) inverse agonist monlunabant, Skye Bioscience CEO Punit Dhillon is confident that their antibody-based approach to CB1 inhibition will make a moot point of the neuropsychiatric side effects that put a damper on Novo's data. On the Business of Biotech, we're digging into the uber-hot business of weight loss therapeutics.

Roche has pushed through so-called "pilot purgatory" and rolled out artificial intelligence solutions in the real world. Two of its data leaders describe three case studies.

Recent advancements in genetic engineering, analytics, and screening reimagine E. coli as an “optimal” protein factory, not just a common one or an expression system artifact.

As we balance the time-to-market and risk for novel therapies, we must anticipate changing needs for combination device development, highlighting the technological paradigm shift.

Once you've identified a CMO partner, how do you ensure success? The secret: planning as early as possible – while your product is still in preclinical or clinical development.

By partnering with a trusted company that offers expertise in navigating the challenges of scale up, drug developers can have confidence in their ability to successfully bring their products to market.

While the Brisbane facility’s key value is facilitating development and industrialization of new bacterial strains, how this is accomplished separates it from would-be competitors.

An experienced CDMO can empower developers to implement de-risking strategies that significantly improve both clinical and commercial outcomes for their biologic and bioconjugate programs.

As drug discovery accelerates, so too does the need for robust cell line development. Learn how a CDMO that prioritizes R&D can help you unlock the potential for faster, more efficient development.

Working with a partner that provides a one-stop shop for bioconjugate development and manufacturing helps prevent missteps that threaten the delivery of life-saving drugs to patients who need them.

Review a CDMO's strategy for overcoming challenges when acquiring new equipment for an Emergency Use Authorization (EUA) project and how leveraging existing resources and collaboration was key.

Poland’s biomanufacturing scene presents an array of benefits for global partnership, including cost-effectiveness, economic stability, and a culture that emphasizes a strong work ethic.

Recombinant protein and plasmid DNA therapeutics and critical raw materials, including for vaccine and gene therapy applications, for the global market.

See how our 4,000-square-foot cGMP manufacturing site is purpose-built to support your microbial program from pre-clinical to commercial manufacturing.

From vector construction to generating cell banks for GMP manufacturing following ICH and global regulatory requirements, we are the experts for all cell line development activities.

With expertise in clinical manufacturing, scale-up, cell cultures, API synthesis, and more, consider our end-to-end development services for pharmaceutical and biotech companies.

Delve into how this partner's scalable packaging services for logistics support can achieve higher operational efficiency and lower quality and safety risks.